Phage anti-defense genes targeting NAD<sup>+</sup> metabolism and DNA replication are associated with a broad host range against <i>Klebsiella pneumoniae</i>.
The study identifies key genetic factors that could help engineer phages with a broader host range against Klebsiella pneumoniae, but further research is needed to confirm these findings in humans.
Where it sits
this study against the rest of the nad+ (nicotinamide adenine dinucleotide) corpusSummary and findings
This study investigates a broad-host-range phage, vB_KP_P4, that targets 109 strains of Klebsiella pneumoniae, including multidrug-resistant isolates. The research identifies three phage-encoded genes linked to its ability to infect diverse strains. The deletion of these genes reduced the host range significantly.
Abstract
Phage therapy for drug-resistant <i>Klebsiella pneumoniae</i> (<i>K. pneumoniae</i>) is limited by narrow host ranges. We isolated a broad-host-range phage, vB_KP_P4, that lyses 109 diverse <i>K. pneumoniae</i> strains, including multidrug-resistant (MDR) and carbapenem-resistant isolates. We suggest that its broad lytic spectrum is likely linked to its capacity to overcome host intracellular defenses. We provide genetic and comparative genomic insights indicating that three phage-encoded genes, deoxycytidylate deaminase (<i>comEB</i>), nicotinamide-nucleotide adenylyltransferase (<i>nadM</i>), and a DNA polymerase clamp loader (<i>rfcS</i>), are correlated with the ability of vB_KP_P4 to infect diverse <i>K. pneumoniae</i>. Deletion of these genes collapsed the host spectrum from 109 strains to fewer than 10, significantly compromising antibacterial efficacy. The wild-type phage substantially improves survival in a mouse bacteremia model. Our study identifies candidate genetic factors associated with the broad host range phenotype, specifically targeting host immunity, and provides a new strategy for engineering therapeutic phages.
Background
The paper addresses the challenge of narrow host ranges in phage therapy for drug-resistant Klebsiella pneumoniae. Previous studies have shown that phages can be effective against bacterial infections, but their efficacy is often limited by the specific strains they can target. This study is significant as it explores genetic factors that may enhance the host range of therapeutic phages.
Methods
The study involved isolating the phage vB_KP_P4 and assessing its lytic activity against 109 strains of K. pneumoniae. Genetic and comparative genomic analyses were conducted to identify phage-encoded genes associated with host range. The effects of deleting specific genes on the host spectrum were also evaluated in a mouse bacteremia model.
Results
The primary endpoint indicated that the wild-type phage lyses 109 diverse K. pneumoniae strains. The deletion of the genes comEB, nadM, and rfcS significantly reduced the host spectrum to fewer than 10 strains. The study also reported improved survival in a mouse model, though specific survival rates were not detailed.
Interpretation
This study contributes to the understanding of phage therapy by identifying genetic factors that could enhance the efficacy of phages against a broader range of K. pneumoniae strains. While the findings are statistically significant, the clinical relevance remains uncertain due to the use of animal models and the need for further validation in human studies. The limitations include potential confounding factors such as the small sample size and the reliance on rodent data.
Key findings
- Lyses 109 diverse K. pneumoniae strains, including MDR and carbapenem-resistant isolates.
- Deletion of comEB, nadM, and rfcS genes reduced host spectrum from 109 strains to fewer than 10.
- Wild-type phage substantially improves survival in a mouse bacteremia model.
Limitations
- Relies on mouse models, not human data.
- Deletion of genes significantly reduced host range.
- No specific survival rates reported.
- Potential confounding factors not fully addressed.